Psychemedics Corp

Psychemedics Corp has a liquidity position characterized by $1.42 million in cash and equivalents and $3.19 million in total liabilities, resulting in a current ratio of 1.82. The company's liquidity is assessed as low, indicating potential challenges in meeting short-term obligations without external financing. The company's debt-to-equity ratio is 0.06, suggesting a conservative capital structure with minimal reliance on debt financing. The company's profitability is underperforming, with a return on equity of -0.3628 and a return on assets of -0.2237, both significantly below the industry median for Healthcare Facilities & Services. These metrics indicate that the company is not generating returns that meet the cost of equity or assets, which is a concern for investors. Psychemedics Corp's revenue is derived from corporate drug testing services and home drug testing kits, with no disclosed segment or geographic breakdown in the provided data. The lack of segment-specific revenue data limits the ability to assess concentration risk or geographic exposure. The company's growth trajectory is unclear due to the absence of historical revenue data and forward-looking guidance. The provided financial snapshot does not include revenue history or outlook for the current or next fiscal year, making it difficult to assess growth potential. Risk factors for Psychemedics Corp include low liquidity and the potential for dilution, although no immediate filing-based liquidity or dilution flags were detected. The company's free cash flow is negative at -$759,000, and capital expenditures are -$87,000, indicating that the company is not generating sufficient cash to fund operations and investments without external financing. Recent events for Psychemedics Corp are not detailed in the provided data, and there are no disclosed filings or transcripts that would provide insight into the company's recent performance or strategic direction.